Development of a predictive score of axillary lymph node dissection based on targeted axillary dissection in patients with breast cancer diagnosis, affected lymph nodes, and neoadjuvant treatment

被引:3
作者
Flores-Funes, Diego [1 ]
Aguilar-Jimenez, Jose [1 ]
Martinez-Galvez, Maria [2 ]
Jose Ibanez-Ibanez, Maria [3 ]
Carrasco-Gonzalez, Luis [1 ]
Ignacio Gil-Izquierdo, Jose [2 ]
Asuncion Chaves-Benito, Maria [4 ]
Ayala-De La Pena, Francisco [5 ]
Nieto-Olivares, Andres [4 ]
Luis Aguayo-Albasini, Jose [1 ]
机构
[1] Morales Meseguer Univ Hosp, Gen Surg Dept, Murcia, Spain
[2] Morales Meseguer Univ Hosp, Radiol Dept, Murcia, Spain
[3] Morales Meseguer Univ Hosp, Nucl Med, Murcia, Spain
[4] Morales Meseguer Univ Hosp, Pathol Dept, Murcia, Spain
[5] Morales Meseguer Univ Hosp, Hematol & Oncol Dept, Murcia, Spain
来源
SURGICAL ONCOLOGY-OXFORD | 2021年 / 38卷
关键词
Breast Neoplasms; Neoadjuvant therapy; Sentinel lymph node biopsy; Clipped node biopsy; Targeted axillary dissection; Axillary lymph node dissection; Predictive score; PATHOLOGICAL COMPLETE RESPONSE; SENTINEL NODE; CHEMOTHERAPY; THERAPY; TRASTUZUMAB; SURGERY; RECIST; TRIAL; IDENTIFICATION; SURVIVAL;
D O I
10.1016/j.suronc.2021.101629
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: To determine predictive factors of axillary lymph node dissection (ALND) results in breast cancer (BC) patients undergoing neoadjuvant chemotherapy (NACT), and subsequent staging using Targeted Axillary Dissection (TAD). Material and method: Case-control study between January 2016 and August 2019. Patients with BC, cN1 staging, marked with a metallic clip prior to NACT, and subsequently staged with TAD and ALND were included. They were divided into 2 groups: ALND patients with or without metastatic involvement (group 1 and group 2, respectively). We carried out a univariate analysis comparing clinical, radiological, surgical and pathological variables, and a logistic regression, (dependent variable: positive result of ALND; independent variables: number of suspicious lymph nodes in diagnostic ultrasound, positive hormone receptors, HER2 positive, complete clinical-radiological response to NACT, positive TAD, and biopsy of <= 2 nodes in TAD). A score for prediction of a metastatic ALND was proposed, with an internal validation study. Results: 60 patients were included: Group 1: 33 (55.0%); Group 2: 27 (45.0%). Tumor size (Odds Ratio (OR) = 1.67; 95%CI 1.02-2.74), number of suspected nodes in ultrasound (OR = 2.20; 95%CI 1.01-4, 77), HER2 positive (OR 0.04; 95%CI 0.003-0.54), clinical-radiological response to NACT (OR = 0.07; 95%CI 0.01-0.75), and positive TAD (OR 15.48; 95%CI 1.68-142.78) were independent predictors of a positive result in ALND. We developed a "positive ALND predictive score", with good calibration (Hosmer-Lemeshow test: p = 0.65), and discrimination (AUC = 0.93; 95% CI 0, 87-0.99), with highest Youden index (0.7) at cut-off point of 17% risk of positive ALND (sensitivity = 100%; specificity = 70%). Conclusion: Tumor size, number of suspected nodes, positive HER2, response to NACT, and metastatic TAD are independent predictors of ALND. The predictive score for positive ALND would be a good indicator to safely omit ALND.
引用
收藏
页数:7
相关论文
共 32 条
[1]   Pre-operative staging of the axilla in primary breast cancer. By redefining the abnormal appearing node can we reduce investigations without affecting overall treatment? [J].
Amonkar, S. J. ;
Oates, E. ;
McLean, L. ;
Nicholson, S. .
BREAST, 2013, 22 (06) :1114-1118
[2]  
[Anonymous], 2013, NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer
[3]   Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy [J].
Baron, Paul ;
Beitsch, Peter ;
Boselli, Danielle ;
Symanowski, James ;
Pellicane, James V. ;
Beatty, Jennifer ;
Richards, Paul ;
Mislowsky, Angela ;
Nash, Charles ;
Lee, Laura A. ;
Murray, Mary ;
de Snoo, Femke A. ;
Stork-Sloots, Lisette ;
Gittleman, Mark ;
Akbari, Stephanie ;
Whitworth, Pat .
ANNALS OF SURGICAL ONCOLOGY, 2016, 23 (05) :1522-1529
[4]   Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy [J].
Barron, Alison U. ;
Hoskin, Tanya L. ;
Day, Courtney N. ;
Hwang, E. Shelley ;
Kuerer, Henry M. ;
Boughey, Judy C. .
JAMA SURGERY, 2018, 153 (12) :1120-1126
[5]   Predicting Non-sentinel Lymph Node Metastases in Patients with a Positive Sentinel Lymph Node After Neoadjuvant Chemotherapy [J].
Barron, Alison U. ;
Hoskin, Tanya L. ;
Boughey, Judy C. .
ANNALS OF SURGICAL ONCOLOGY, 2018, 25 (10) :2867-2874
[6]   Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance) [J].
Boughey, Judy C. ;
Ballman, Karla V. ;
Le-Petross, Huong T. ;
McCall, Linda M. ;
Mittendorf, Elizabeth A. ;
Ahrendt, Gretchen M. ;
Wilke, Lee G. ;
Taback, Bret ;
Feliberti, Eric C. ;
Hunt, Kelly K. .
ANNALS OF SURGERY, 2016, 263 (04) :802-807
[7]   Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer The ACOSOG Z1071 (Alliance) Clinical Trial [J].
Boughey, Judy C. ;
Suman, Vera J. ;
Mittendorf, Elizabeth A. ;
Ahrendt, Gretchen M. ;
Wilke, Lee G. ;
Taback, Bret ;
Leitch, A. Marilyn ;
Kuerer, Henry M. ;
Bowling, Monet ;
Flippo-Morton, Teresa S. ;
Byrd, David R. ;
Ollila, David W. ;
Julian, Thomas B. ;
McLaughlin, Sarah A. ;
McCall, Linda ;
Symmans, W. Fraser ;
Le-Petross, Huong T. ;
Haffty, Bruce G. ;
Buchholz, Thomas A. ;
Nelson, Heidi ;
Hunt, Kelly K. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 310 (14) :1455-1461
[8]   Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer [J].
Buzdar, AU ;
Ibrahim, NK ;
Francis, D ;
Booser, DJ ;
Thomas, ES ;
Theriault, RL ;
Pusztai, L ;
Green, MC ;
Arun, BK ;
Giordano, SH ;
Cristofanilli, M ;
Frye, DK ;
Smith, TL ;
Hunt, KK ;
Singletary, SE ;
Sahin, AA ;
Ewer, MS ;
Buchholz, TA ;
Berry, D ;
Hortobagyi, GN .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) :3676-3685
[9]   Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study [J].
Campiglio, Manuela ;
Bufalino, Rosaria ;
Sandri, Marco ;
Ferri, Elisa ;
Aiello, Rosa Anna ;
De Matteis, Andrea ;
Mottolese, Marcella ;
De Placido, Sabino ;
Querzoli, Patrizia ;
Jirillo, Antonio ;
Bottini, Alberto ;
Fantini, Manuela ;
Bonetti, Andrea ;
Pedani, Fulvia ;
Mauri, Maria ;
Molino, Annamaria ;
Ferro, Antonella ;
Pupa, Serenella M. ;
Sasso, Marianna ;
Menard, Sylvie ;
Balsari, Andrea ;
Tagliabue, Elda .
BREAST CANCER RESEARCH AND TREATMENT, 2011, 128 (01) :147-154
[10]   Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection [J].
Caudle, Abigail S. ;
Yang, Wei T. ;
Krishnamurthy, Savitri ;
Mittendorf, Elizabeth A. ;
Black, Dalliah M. ;
Gilcrease, Michael Z. ;
Bedrosian, Isabelle ;
Hobbs, Brian P. ;
DeSnyder, Sarah M. ;
Hwang, Rosa F. ;
Adrada, Beatriz E. ;
Shaitelman, Simona F. ;
Chavez-MacGregor, Mariana ;
Smith, Benjamin D. ;
Candelaria, Rosalind P. ;
Babiera, Gildy V. ;
Dogan, Basak E. ;
Santiago, Lumarie ;
Hunt, Kelly K. ;
Kuerer, Henry M. .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (10) :1072-+